List of Gene Editing/CRISPR Companies in California - 86

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Apton is a California-based biotechnology company that manufactures and supplies single-molecule detection and sequencing imaging systems for clinical applications.

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

ASC Therapeutics focuses on the development of curative therapies for rare diseases. Our gene, CRISPR and cell therapies were developed at Applied StemCell, a life sciences company for over 12 years, including proprietary gene editing technologies. Our development pipeline includes several preclinical stage projects focusing on monogenic blood disorders that exhibit a high genetic penetrance and conditions requiring immunomodulatory interventions. Contact us for partnership opportunities

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

We are Basilard BioTech. We have introduced our novel gene delivery technology platform, Celletto™ to transform the rapidly growing cell-based therapies market. Celletto™ is a differentiated & superior solution for non-viral gene delivery. Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies. This is the bottleneck Celletto™ addresses with our new, disruptive, IP-Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. In ex-vivo delivery, Celletto™ consistently achieves higher transfection and cell viability performance and yields vs. the industry leading bulk electroporation platform currently used widely. In viral delivery, Celletto™ provides greater scalability, safety, efficiency, & versatility than prevailing viral delivery methods, as well as lower cost & lead time. And Celletto™ is a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods.

Beeflow creates nature based solutions to help farmers improve the impact of pollination in agriculture by leveraging scientific knowledge and technology. Pollination is critical to crop success as it sets the ceiling for crop yield and quality potential. Inefficient or lack of pollination can reduce crop yields, cause malformation and small-sized crops, contribute to fruit diseases and ultimately increase food waste.

Blacksmith Medicines is a biotechnology company focused on creating medicines targeting metalloenzymes. They have announced a merger with Forge Therapeutics to further their mission.

Cairn Biosciences discovers new medicines by mapping multiscale cell dynamics. Our proprietary COMPASS™ discovery platform unlocks exclusive routes to novel targets and drugs by navigating uncharted, complex and dynamic disease biology. Using COMPASS, our diverse, multidisciplinary team of experts in drug discovery, disease biology, engineering and computation is pioneering a new drug discovery paradigm that utilizes our innovative simulations of living biology to deliver better therapeutics. We are initially orienting COMPASS to the exciting challenge of discovering new drugs that overcome acquired resistance to targeted cancer therapies. Cairn \​'kern\ a stone beacon marking the direction of a trail.

Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research. We are committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. Our unique, cutting-edge products are currently used around the world in the research laboratories of universities, government institutes, biotechnology and pharmaceutical companies

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Here at CRISPR QC, we empower scientists using CRISPR to solve the world's great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.

Epic Bio is a biotechnology company that focuses on biomedical research and genetics.

ePlant is revolutionizing how the world understands and cares for plants. Our cutting-edge TreeTag sensors provide real-time insights into plant growth, water stress, and environmental responses. By empowering growers, arborists, and researchers with the precise data they need, our technology enables optimized plant health, informed decision-making, and maximized yields. Discover more at ePlant.bio.

Developing transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond traditional gene sequencing to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies.

GenEdit is revolutionizing genetic medicines by developing innovative therapies through targeted delivery of genetic medicines.

GenTarget is a biotech company that specializes in lentivirus products for various applications.

GenVivo will make first- and best-in-class immune therapies that are immediately and easily deployable, highly effective, and which improve survival and quality of life beyond current therapies.

Our mission is to use visionary science and technology to overcome major unsolved diseases.

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.

Founded by Jennifer Doudna, the Innovative Genomics Institute advances genome engineering to cure disease and ensure food security.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

At Intrinsyx Bio, we are commercializing 3 decades of the leading academic research in the plant microbiome. Our endophytic microbes cause crop plants, grasses, ornamental plants, and trees to fix Nitrogen (N2) directly from the atmosphere into ammonia which helps improve nutrient use efficiency, supplement synthetic fertilizer requirements, and increase chlorophyll. These microbes live in leaves, stems, roots and don't require a nodule. Our endophyte microbes also mobilize insoluble phosphorous (P2) from soil into roots, as well as increase drought and salt tolerances.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.

Kimia Therapeutics is generating a chemical atlas for treating human disease. Kimia's ATLAS is the key to druggable space, unlocking the potential of generative chemistry. The company is focused on drug discovery and developing disease-modifying therapies for metabolic diseases.

Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.

Light Horse is leading the way in precision genome editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that play critical roles in disease biology. The high-throughput discovery platform systematically interrogates complex signaling pathways to uncover unique sites of vulnerability. Light Horse interrogates these targets in their native, cellular context to best ensure that discoveries in the lab translate into the clinic.

Living Carbon is working to fight climate change by using genetic engineering with trees to improve CO2 capture and storage.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

MEDIC Life Sciences is a biotechnology company that specializes in resurrecting cancer drugs from failed clinical trials using proprietary technology to produce 2 million different tumor samples for testing.

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of Molecular Assemblies, Inc.

We developed a new technology for enzymatic production of high quality, long and even functionalized DNA molecules, which will have a huge impact on industrial synthetic biology, precision diagnostics, therapeutics and nanotechnology. DNA oligonucleotides are commonly synthesized by solid phase, but after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nucleotides, with further limitations in terms of purity and efficacy in presence of strong secondary structures or repeats. The advances and improvements in diagnostic and therapeutic systems based on nucleic acids are leading to a big and urgent need of highly pure and long DNA strands, and Moligo Technologies mission is to satisfy this necessity. In fact, thanks to our know-how, and to the capacity of experienced scientific and executive team, we are already able to synthesize, and very soon commercialize, single stranded oligonucleotides of thousands of bases with purity of about 99.9%.

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX's therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

Biotech startup developing cutting edge therapies for muscle diseases

We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Norfolk is developing the next generation of innovative vegetables and fruits, to meet the needs of consumers and the environment. We believe in bringing sustainable health to everyone, with appealing foods powered by bioengineering.

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

One Genomics is a CRISPR based gene editing company focused on developing transformative gene editing tools and therapies using its proprietary editing technologies, allowing for precise changes to genomic DNA.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

Pando Nutrition is a company in the livestock production industry that develops next generation probiotics to accelerate the transition towards antibiotic-free production, fighting disease, enhancing growth, and improving nutrition for animals.

Papillon Therapeutics is a clinical stage biotechnology company advancing multi-systemic genetic medicines for diseases with neurologic, cardiac, and other tissue pathologies, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Inherited conditions often cause degeneration of multiple tissues throughout the body, inspring our approach to develop therapies that offer patients lifelong multi-systemic therapeutic benefit from a single treatment. Our clinical stage program, a gene modified hematopoietic stem and progenitor cell (HSPC) therapy for treatment of Cystinosis, reported positive data in a Phase 1/2 clinical trial and is being advanced by Novartis. Building on this success, we are advancing gene modified HSPC treatments for life threatening conditions with neurologic disease, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Funding awarded by the California Institute of Regenerative Medicine (CIRM) and NIH to our scientific founders totals over $30 million towards the Cystinosis, Friedreich's ataxia, and Danon disease programs.

Pheronym is an Ag-biotech company that develops green solutions for agricultural pest control. Without pesticides, farmers would experience 50-80 % crop loss. Farmers have to use pesticides to feed the world and stay in business. Our technology uses nematode's own pheromones to control their behavior and development. We have a new additive that makes commercially available nematodes more effective bio-pesticides for insect control.

Plant Sciences Inc is dedicated to being the leading provider of superior berry genetics worldwide. Its focus is the development, propagation and technical support of its premier strawberry, raspberry and blackberry varieties. Working closely with licensed growing partners and regional master license propagators, Plant Sciences serves a discriminating portfolio of fruit producers and marketers around the globe.

Our mission at Poseida Therapeutics is to create cell and gene therapies with the capacity to cure. We are developing novel products using our broad gene engineering platform technologies, with the goal of bringing new and better treatments to patients with serious diseases, first in the blood-based cancer Multiple Myeloma and next in solid tumors like prostate cancer.

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.

Pyrone Systems is developing technologies to use biology plus chemistry to make chemicals that are not only sustainable and safe, but that outperform existing petrochemicals. Stay tuned for updates as we unveil our first product in the near future.

Radar Therapeutics is a biotech company developing programmable precision therapeutics using molecular RNA sensors. The company has raised $13.4 million in seed funding to support its work in developing smart, programmable medicines. Radar Therapeutics is also the winner of the first-ever Amgen Bakar Labs Diversity, Inclusion, and Belonging Award. The company is building a business around medicines that use RNA sensors—mRNAs that gate their expression based on other RNAs in the cell.

Rancho Tissue Technologies produces tissue-cultured, custom propagated plants, food crops, and medicinal plants.

Sangamo Therapeutics is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The optionality and diversity inherent to Sangamo’s technology platform enables us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment. Because Sangamo’s technology platforms are related, we are applying learnings across studies to optimize each individual platform and uncover research and development paths forward. Sangamo is best known for developing our proprietary gene editing technology, zinc finger nucleases (ZFNs). Our technology team continues to optimize ZFNs for the three key dimensions of genome editing: precision, efficiency, and specificity. Ex vivo gene-edited cell therapy is the most straightforward application of ZFN technology. It builds on early experience with HIV clinical studies and is applied to hematological disorders and oncology. Our cell therapy portfolio also includes ex vivo engineered regulatory T-cells (CAR-Tregs) for application in autoimmunity and inflammation. The insights gained about molecular biology, cassette engineering, and delivery through in vivo application of ZFNs led to our gene therapy program using AAV, which is advancing in the clinic. Zinc finger protein engineering and AAV delivery are also foundational for our zinc finger protein-transcription factor (ZFP-TF) genome regulation technology, which we are applying in CNS diseases. With our robust history of genomic medicine firsts, unmatched technology platform, and growing manufacturing and clinical development capabilities, Sangamo believes we are the company to realize the vision of genomic medicine.

Scribe is building and applying a suite of CRISPR technologies designed for therapeutic use into a single continually evolving and expanding genetic modification platform. Specifically, the company is working on NK cell therapies.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

We are improving how we farm and what we eat by unleashing the natural power that exists in plants to create a more agile and resilient agriculture system.

Synthego is a genome engineering company enabling the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. By vertically integrating hardware, software, bioinformatics, chemistry, and molecular biology, Synthego is at the forefront of innovation advancing the next generation of medicines through providing access to genome editing at an unprecedented scale. //// Our Culture of Diversity: Different Faces from Different Places At Synthego, our differences make us unique, help us innovate, and allow us to persevere. We stand firmly behind our values, strive to achieve representation, and celebrate diversity in perspectives and backgrounds. We welcome all team members to be their best selves as we move forward towards fulfilling our shared vision of revolutionizing genome engineering technology to help make biological therapies accessible to all patients.

A biotechnology platform to develop safe, scalable, and effective solutions to eliminate disease-transmitting vectors, starting with the world's deadliest animal: the mosquito.

At SBI, our mission is to accelerate your science by turning the latest insights and technologies into robust research products and services to advance exosome studies, biomarker research, gene delivery, SARS-CoV-2 studies, and more.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Taxa Technologies is a probiotics company that aims to revolutionize the understanding of microbiome engineering. They are focused on designing probiotics for personal care and enabling cheaper, faster, and better genetic engineering.

THC Design is the leader in premium cannabis cultivation. Estate grown, single-sourced flower provides consistent experiences with quality and safety across a wide spectrum of brands. Through moral and corporate transparency, THC Design aims to inspire each person and community through the art and science of flower. By partnering with leading scientists in various fields, THC Design hopes to break new ground in the cannabis industry. We are committed to making scientific advances in identifying the roles of not only THC and CBD, but also the dozens of other therapeutic compounds in cannabis. This will help us develop better plants that can more accurately treat disease and ailments. Building a community and contributing our voice to the cannabis industry is extremely important to us. We support national and local advocacy groups to address legalization, access, and research of cannabis. We meet with lawmakers and policy writers to ensure fairness in the ongoing organization and regulation of cannabis in California.

ThinkCyte's mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enable the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.

Trace Genomics is a pioneer in the use of hi-definition genomics to activate the hidden insights in soil for healthier soils and a healthier planet. Through innovation in genomics, soil science and machine learning, Trace Genomics creates a pathway to deliver targeted database insights and actions at cost-speed-scale-accuracy for partners who are advancing modern farming solutions for a net-zero food production system. Where most companies deliver a partial picture, we provide a comprehensive and precise understanding of the soil’s composition—analyzing the soil’s biology, physical properties and chemistry. Trace Genomics has won several awards, including being selected as a 2020 Technology Pioneer by the World Economic Forum, Winner of FoodShot Global’s Innovating Soil 3.0 Challenge, Forbes Top 25 Most Innovative AgTech, THRIVE Top 50 AgTech, 2022 Global Cleantech top 100 start-ups and many more.

Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.

VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world. The company was founded by Dr. Samantha Du, Chairperson and CEO, in 2014 to help address significant unmet medical needs in China and to be at the forefront of medical innovation.